MIRA
INFORM REPORT
|
Report Date : |
18.01.2012 |
IDENTIFICATION DETAILS
|
Name : |
ILYANG PHARMACEUTICAL CO., LTD. |
|
|
|
|
Registered Office : |
182-4, Hagal-dong, Giheung-gu, Yongin-si,
Gyeonggi-do, Korea 446-726 |
|
|
|
|
Country : |
South Korea |
|
|
|
|
Financials (as on) : |
30.09.2011 |
|
|
|
|
Date of Incorporation : |
30.12.1971 |
|
|
|
|
Com. Reg. No.: |
209-81-00872 |
|
|
|
|
Legal Form : |
Listed Company |
|
|
|
|
Line of Business : |
Manufacture of Medicinal Medicaments |
|
|
|
|
No. of Employees : |
641 |
RATING & COMMENTS
|
MIRAs Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Good |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List September 30, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
South Korea |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Basic Information
|
Company Name |
ILYANG PHARMACEUTICAL CO., LTD. (Korean Company Name : 일양약품(주)) |
|
Registered Address |
182-4, Hagal-dong, Giheung-gu, Yongin-si,
Gyeonggi-do, Korea |
|
Zip Code |
446-726 |
|
Tel |
+82-31-281-7851 |
|
Fax |
+82-31-284-8141 |
|
E-mail |
webmaster@ilyang.co.kr |
|
Website |
www.ilyang.co.kr |
|
Trading Address |
Ilyang B/D., 544-5, Dogok-dong,
Gangnam-gu, Seoul, Korea |
|
Tel |
+82-2-570-3700~7 |
|
Fax |
+82-2-570-3708~9 |
|
Other Address-Gunsan Factory |
88, Balsan-ri, Gaejeong-myeon, Gunsan-si,
Jeollabuk-do, Korea |
|
Tel |
+82-654-43-1001~5 |
|
Fax |
+82-654-43-1010 |
|
Other Address-Jeonbuk Branch |
1140-1, Yeoui-dong, Deokjin-gu, Jeonju-si,
Jeollabuk-do, Korea |
|
Tel |
+82-63-211-1500 |
|
Other Address-Daejeon Branch |
22-4, Yongjeon-dong, Dong-gu, Daejeon, Korea |
|
Tel |
+82-42-622-9386 |
|
Other Address-Gyeong-in Branch |
34-10, Sinheungdong 1-ga, Jung-gu, Incheon, Korea |
|
Tel |
+82-32-887-8590 |
|
Other Address-Daegu Branch |
353-9, Bolli-dong, Dalseo-gu, Daegu, Korea |
|
Tel |
+82-53-527-6681 |
|
Other Address-Gwangwon Branch |
898-2, Hakseong-dong, Wonju-si, Gangwon-do, Korea |
|
Tel |
+82-33-748-1010 |
|
Type |
Export/Import |
|
Industry |
Manufacture of Medicinal Medicaments |
|
Main Business |
Medicine, Full Text Medicine, Raw Material Medicine |
|
Established (mm/dd/yyyy) |
12/30/1971 |
The Subject owns
the premises of registered HQ address/Factory(59,531㎡) and Gunsan Factory(20,593㎡).
Detailed Products
|
Activity |
Detailed Products (UNSPSC) |
|
Sell |
Vitamin supplements(51191905) |
|
Sell |
Antacids and antiflatulents(51171500) |
|
Sell |
Non narcotic analgesics and antipyretics(51142000) |
|
Sell |
Antihistamines or H1 blockers(51161600) |
|
Sell |
Thrombolytic drugs and platelet aggregation inhibitors(51131700) |
|
Sell |
Sport or energy drink(50202309) |
|
Sell |
Antacids and antiflatulents(51171500) |
|
Sell |
Centrally acting skeletal muscle relaxants(51151900) |
|
Sell |
Nonsteroidal anti inflammatory drugs NSAIDs(51142100) |
|
Sell |
Ophthalmic(51102400) |
|
Sell |
Lip balm(53131630) |
CEOs
|
Name |
Jung Do-Uhn |
|
Date of Birth |
02/07/1948 |
|
Title |
Chairman & CEO |
|
Sex |
Male |
|
Nationality |
Korean |
Profiles
|
Capital (KRW) |
44,847,025,000 |
|||||||||||||||
|
Employees |
641 |
|||||||||||||||
|
Formation |
Listed Company (Korea Stock Exchange :
007570) as of 08/28/1974 A Company of
ILYANG
PHARMACEUTICAL CO., LTD. |
|||||||||||||||
|
Bank Details |
Hana Bank Korea Development Bank Kookmin Bank-Shingal Branch Nonghyup Bank Woori Bank |
|||||||||||||||
|
Corporate Registered No. |
110111-0124802 |
|||||||||||||||
|
Business Registered No. |
209-81-00872 |
|||||||||||||||
|
Permit & Licenses |
Intl Trade No.: 803489 |
|||||||||||||||
|
Shareholder Position |
|
|||||||||||||||
|
Company History |
07/1946 Established as GONGSHIN YAKUPSA CO. 07/01/1957 Changed company name to SUNLIM
YAKUP SA CO. 04/10/1960 Changed company name to IL YANG
PHARM MFG. CO. 06/15/1961 Changed company name to IL YANG
PHARMACEUTICAL MFG. CO. 12/30/1971 Incorporated as IL YANG
PHARMACEUTICAL INDUSTRIES CO., LTD. 05/28/1991 Changed company name to the
present name 05/20/2005 Moved to the present HQ address
from 185-3, Dongcheon-dong, Suji-gu, Yongin-si, Gyeonggi-do, Korea |
|||||||||||||||
|
|
|
Management
|
Job Description |
Title |
Name |
Nationality |
Date of Birth |
Education |
|
Chairman & CEO |
Mr. |
Jung Do-Uhn |
Korean |
1948. 02.07 |
Chungang University, Korea |
|
President & CEO |
Mr. |
Kim Dong-Yon |
Korean |
1950.0 8.19 |
Hanyang University, Korea |
|
Director |
Mr. |
Jung Yoo-Seok |
Korean |
1976.08.23 |
New York University, USA |
|
Outside Director |
Mr. |
Juoo Seung-Nam |
Korean |
1943. 08.08 |
Yonsei University, Korea |
|
Outside Director |
Mr. |
Bae Myung-Sik |
Korean |
1947. 06.01 |
Yonsei University, Korea |
|
Outside Director |
Mr. |
Woo Jae-Young |
Korean |
1945.12.01 |
Cheonbuk National University, Korea |
Financials
|
Year / Unit : KRW |
Sales |
Assets |
Net Income |
|
71,884,262,711 |
352,418,873,555 |
606,593,157 |
|
|
03/2011 |
138,485,382,468 |
315,552,190,885 |
1,975,802,243 |
|
03/2010 |
135,952,738,420 |
282,542,987,916 |
1,065,747,662 |
|
03/2009 |
114,614,743,355 |
267,294,223,053 |
-16,079,810,910 |
|
03/2008 |
120,289,302,324 |
175,056,838,141 |
1,003,251,556 |
|
03/2007 |
129,862,633,939 |
158,541,870,126 |
3,110,882,596 |
|
03/2006 |
120,279,868,421 |
153,069,510,373 |
3,479,549,629 |
|
03/2005 |
109,147,890,913 |
186,279,327,567 |
1,863,111,638 |
(*)09/2011 s figures are based on the K-IFRS Accounting System.
Financial Description
|
Authorized Capital(KRW) |
100,000,000,000 |
|
Paid-Up Capital(KRW) |
44,847,025,000 |
|
Total Issued Shares |
17,938,810 (Common : 17,493,730 / Preferable : 445,080) |
Balance
Sheet
|
Unit :
Korean Won |
04/01/2011~09/30/2011 |
As of 03/31/2010 |
As of 03/31/2009 |
|
Total
Assets |
352,418,873,555 |
320,522,794,022 |
|
|
Current Assets |
123,878,963,256 |
109,463,219,171 |
|
|
Cash
& Cash Equivalents |
9,241,438,437 |
8,973,617,574 |
|
|
Trade
Receivables & Other Receivables |
82,030,428,065 |
75,764,874,210 |
|
|
Inventories |
29,412,348,825 |
23,590,534,118 |
|
|
Marketable
Financial Instruments |
1,426,000,000 |
1,115,000,000 |
|
|
Current
Financial Instruments |
1,768,747,929 |
19,193,269 |
|
|
Non-Current Assets |
228,539,910,299 |
211,059,574,851 |
|
|
Marketable
Financial Instruments |
1,771,179,398 |
1,764,062,023 |
|
|
Non-Current
Financial Instruments |
3,135,704,397 |
4,297,739,788 |
|
|
Non-Current
Non-Financial Instruments |
9,719,948,783 |
8,913,941,914 |
|
|
Other Investment Equity Assets |
6,143,713,134 |
4,933,525,040 |
|
|
Tangibles |
166,799,899,610 |
150,924,152,937 |
|
|
Intangibles |
17,391,126,898 |
15,283,318,288 |
|
|
Investment_Real
Estates |
23,578,338,079 |
24,942,834,861 |
|
|
Total Liabilities |
183,580,115,446 |
195,192,545,050 |
|
|
Current Liabilities |
104,738,692,416 |
165,441,983,392 |
|
|
Trade
Payables & Other Payables |
24,193,603,089 |
36,128,211,177 |
|
|
Other
Current Financial Debts |
4,736,977,070 |
4,894,299,746 |
|
|
Short-Term
Borrowings |
37,466,000,000 |
45,930,759,434 |
|
|
Current
Portion of Provisions |
842,112,257 |
786,264,247 |
|
|
Current Portion of Long-Term Borrowings |
37,500,000,000 |
77,702,448,788 |
|
|
Non-Current Liabilities |
78,841,423,030 |
29,750,561,658 |
|
|
Other
Non-Current Financial Debts |
62,625,000,000 |
14,375,000,000 |
|
|
Provision
for Severance & Retirement |
4,746,241,391 |
4,096,461,191 |
|
|
Deferred
Income Tax Credit |
11,470,181,639 |
11,279,100,467 |
|
|
Capital Stock |
44,847,025,000 |
36,369,015,000 |
|
|
Capital
Surplus |
66,416,968,461 |
30,488,721,298 |
|
|
Installments |
62,510,252,744 |
62,335,535,060 |
|
|
Treasury Stock |
-7,350,117,284 |
-7,057,916,284 |
|
|
Profit
Surplus |
1,264,629,188 |
3,194,893,898 |
|
|
Others |
1,150,000,000 |
0 |
|
|
Total
Equity |
168,838,758,109 |
125,330,248,972 |
|
|
Liab.
& Shareholders Equity |
352,418,873,555 |
320,522,794,022 |
|
Balance
Sheet
|
Unit : Korean Won |
As of 03/31/2010 |
As of 03/31/2009 |
As of 03/31/2008 |
|
Total Assets |
315,552,190,885 |
282,542,987,916 |
267,294,223,053 |
|
Current Assets |
105,469,954,568 |
102,158,824,005 |
103,120,652,549 |
|
-Quick Assets |
81,879,420,450 |
81,012,664,808 |
84,030,726,670 |
|
-Inventories |
23,590,534,118 |
21,146,159,197 |
19,089,925,879 |
|
Fixed Assets |
210,082,236,317 |
180,384,163,911 |
164,173,570,504 |
|
-Investment |
8,611,767,800 |
6,853,144,698 |
7,139,471,055 |
|
-Tangibles |
174,889,649,264 |
149,420,926,131 |
146,304,764,530 |
|
-Intangibles |
13,388,908,269 |
11,732,123,358 |
7,721,229,052 |
|
-Others |
13,191,910,984 |
12,377,969,724 |
3,008,105,867 |
|
Total Liabilities |
190,382,692,008 |
159,837,191,010 |
147,846,232,461 |
|
Current Liabilities |
161,511,223,958 |
96,543,529,170 |
92,610,092,425 |
|
Fixed Liabilities |
28,871,468,050 |
63,293,661,840 |
55,236,140,036 |
|
Capital Stock |
36,369,015,000 |
36,369,015,000 |
36,369,015,000 |
|
Capital Surplus |
30,488,721,298 |
30,477,884,840 |
41,339,419,258 |
|
Profit Surplus |
2,909,078,904 |
1,030,672,233 |
-12,575,605,523 |
|
Capital Adjustment |
55,402,683,675 |
54,828,224,833 |
54,315,161,857 |
|
Total Equity |
125,169,498,877 |
122,705,796,906 |
119,447,990,592 |
|
Liab. & Shareholders Equity |
315,552,190,885 |
282,542,987,916 |
267,294,223,053 |
Income
Statement
|
Unit : Korean Won |
04/01/2011~09/30/2011 |
As of 03/31/2010 |
As of 03/31/2009 |
|
Sales |
71,884,262,711 |
|
|
|
Cost of Sold Goods |
42,832,837,650 |
|
|
|
Gross Profit |
29,051,425,061 |
|
|
|
Selling & Admin. Expenses |
26,639,420,372 |
|
|
|
Other Operating Income |
1,630,656,371 |
|
|
|
Other Operating Expenses |
556,685,712 |
|
|
|
Operating Income |
3,485,975,348 |
|
|
|
Finance Income |
798,668,209 |
|
|
|
Finance Expenses |
3,474,701,756 |
|
|
|
Income Before Taxes |
809,941,801 |
|
|
|
Income Taxes Expenses |
203,348,644 |
|
|
|
Net Income |
606,593,157 |
|
|
Income
Statement
|
Unit : Korean Won |
As of 03/31/2011 |
As of 03/31/2010 |
As of 03/31/2009 |
|
Sales |
138,485,382,468 |
135,952,738,420 |
114,614,743,355 |
|
Cost of Sold Goods |
79,988,287,203 |
83,961,904,896 |
77,283,176,385 |
|
Gross Profit |
58,497,095,265 |
51,990,833,524 |
37,331,566,970 |
|
Selling & Admin. Expenses |
52,574,428,169 |
47,764,828,251 |
49,323,409,804 |
|
Operating Income |
5,922,667,096 |
4,226,005,273 |
-11,991,842,834 |
|
Non-Operating Income |
5,213,480,175 |
6,159,201,752 |
7,396,648,194 |
|
Non-Operating Expenses |
8,022,263,849 |
7,869,132,653 |
15,258,117,538 |
|
Income Before Taxes |
3,113,883,422 |
2,516,074,372 |
-19,853,312,178 |
|
Income Taxes Expenses |
1,138,081,179 |
1,450,326,710 |
-3,773,501,268 |
|
Net Income |
1,975,802,243 |
1,065,747,662 |
-16,079,810,910 |
Cash
Flows
|
Unit :
Korean Won |
04/01/2011~09/30/2011 |
As of 03/31/2010 |
As of 03/31/2009 |
|
Operating Activities Cash Flows |
-23,526,958,727 |
|
|
|
Net
Income |
606,593,157 |
|
|
|
Adjustment |
-24,133,551,884 |
|
|
|
Cash
Flows from Investing |
-19,165,435,695 |
|
|
|
Cash
Flows from Financing |
42,960,215,285 |
|
|
|
Increase/Decrease
in Cash |
267,820,863 |
|
|
|
Cash
at the Beginning of Year |
8,973,617,574 |
|
|
|
Cash
at the End of Year |
9,241,438,437 |
|
|
Cash
Flows
|
Unit :
Korean Won |
As of 03/31/2011 |
As of 03/31/2010 |
As of 03/31/2009 |
|
Cash Flows
from Operating |
15,474,103,691 |
-11,394,622,157 |
-1,631,673,213 |
|
-Net Income |
1,975,802,243 |
1,065,747,662 |
-16,079,810,910 |
|
-Exp.
without Cash Outflow |
6,918,985,441 |
6,281,077,474 |
12,953,643,994 |
|
-Revenue
without Cash Inflows |
-1,484,317,305 |
-1,258,593,282 |
-1,058,174,882 |
|
-Changes in
Asset/ & Liability |
8,063,633,312 |
-17,482,854,011 |
2,552,668,585 |
|
Cash Flows
from Investing |
-34,356,119,609 |
-19,380,605,824 |
-13,183,440,924 |
|
-Cash Inflow
from Investing |
61,547,732,012 |
53,391,153,250 |
49,182,923,835 |
|
-Cash
Outflows for Investing |
-95,903,851,621 |
-72,771,759,074 |
-62,366,364,759 |
|
Cash Flows
from Financing |
11,965,826,270 |
27,848,427,143 |
22,655,578,674 |
|
-Cash
Inflows from Financing |
48,000,571,477 |
97,371,527,757 |
72,852,500,000 |
|
-Cash
Outflows from Financing |
-36,034,745,207 |
-69,523,100,614 |
-50,196,921,326 |
|
Increase/Decrease
in Cash |
-6,916,189,648 |
-2,926,800,838 |
7,840,464,537 |
|
Cash at the
Beginning of Year |
15,889,807,222 |
18,816,608,060 |
10,976,143,523 |
|
Cash at the
End of Year |
8,973,617,574 |
15,889,807,222 |
18,816,608,060 |
Products, Technologies, Services Description
|
Main Products & Services |
Drugs for geriatric or menopausal disease Drugs acting on circulatory system /
Hypertension Diuretics / Drugs for liver disease / Drugs
for Gastro-intestinal system Anthelmintics / A cold remedy drugs acting
on respiratory system Analgesics, antipyretics &
anti-inflammatory agents Total Parenteral Nutrition Anti-fungal agent/antibiotics Digestive agents Antacids/ drugs for gastric ulcer/
antispasmodic Vitamins / Tonics/ health drink Peridontitis / Opthalmic Solutions Anti-histamines& Anti-emetics /
Miscellaneous Agent for allergy / Psychiatric Health care products / Arthritis Agent |
Trade Partners & Competitors
|
Suppliers |
DOOSAN TECHPACK CO., LTD.(110111-00292420 ABBOTT KOREA LTD.(110111-0575948) |
|
Competitors |
DAEWOONG PHARMA CO., LTD.(134811-0075342) 223-23, SANGDAEWON 1-DONG, JUNGWON-GU, SEONGNAM-SI, GYEONGGI-DO, KOREA TEL:+82-31-741-7700~4
FAX:+82-31-749-5535 ILDONG PHARMACEUTICAL CO., LTD(110111-0012776) 60, YANGJAE 1-DONG, SEOCHO-GU, SEOUL, KOREA TEL:+82-2-526-3114
FAX:+82-2-526-3030 DONGWHA PHARM IND CO., LTD.(110111-0043870) 5, SUNHWA-DONG, JUNG-GU, SEOUL, KOREA TEL:+82-2-2021-9300 FAX:+82-2-776-7873 |
Related Parties
(Subsidiaries,
Joint-Venture & Affiliates)
|
Affiliates |
KHANTECH CO., LTD.(110111-1076078) (12.5% held by the subject company) TONGHUA IL-YANG HEALTH PRODUCTS CO.,
LTD.(CHINA) (45.9% held by the subject company) IL YANG BIO PHARM CO., LTD.(151211-0022360) |
|
Subsidiary |
HANBO MEDICAL CO., LTD.(134811-0014548) (98.2% held by the subject company) YANGZHOU ILYANG PHARMACEUTICAL CO., LTD.-CHINA (52.0% held by the subject company) ILYANG(SHANGHAI) INTERNATIONAL CO., LTD. (60.0% held by the subject company) |
|
Cooperative Enterprise |
TAP-USA PFIZER-USA SCHWARZ PHARMA-GERMANY LIPZON PHARM-CHINA INTERCURE-USA ALLIANCE-USA URIACH & CIA-SPAIN GENTEC-SPAIN -Insured Company DONGBU INSURANCE CO., LTD.(110111-0095285) HEUNGKUK FIRE & MARINE INSURANCE CO., LTD.(110111-0016728) LIG INSURANCE CO., LTD(110111-0017859) FIRST FIRE & MARINE INSURANCE CO., LTD(110111-0017586) HYUNDAI MARINE & FIRE INSURANCE CO., LTD.(110111-0035893) |
Sales by Region
(Activity &
Markets)
|
Sales/ Unit :Mil KRW |
09/2011 |
03/2011 |
03/2010 |
|
Export |
7,403 |
13,128 |
13,336 |
|
Domestic |
64,481 |
125,357 |
122,617 |
|
Total |
71,884 |
138,485 |
135,953 |
The Subject exports
to Afghanistan, Vietnam, Germany, USA, China, Canada, New Zealand, Indonesia,
Bangladesh, Japan and Argentina.
Court Action
No.
News Clipping
--
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.51.06 |
|
|
1 |
Rs.78.48 |
|
Euro |
1 |
Rs.64.99 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SCs credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.